Genocea announced back in September that its interim results for its 140 patient Phase 1/2 generated T-cell responses, as well reductions in viral sheddings.
Vical has just started recruiting.
Did GSK's failed Phase 3 HerpeVac illicit a T-cell response?
It should be noted Bill Halford is not impressed with Genocea's results. Having said that, I don't think he's impressed with any programs except his own.
updated ballieu report - target range 25-55c, page-49
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$17.05 |
Change
-0.300(1.73%) |
Mkt cap ! $327.7M | |||
| Open | High | Low | Value | Volume |
| $17.00 | $17.44 | $16.95 | $184.6K | 10.84K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 191 | $17.15 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $17.50 | 500 | 1 |
View Market Depth
| Last trade - 15.59pm 19/07/2024 (20 minute delay) ? |
| AVR (ASX) Chart |